Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cannabinoid receptor 2 agonist
- Development stage
- Preclinical
- Lead developer
- Warren Center for Neuroscience Drug Discovery
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
The cannabinoid receptor 2 (CB2) agonist program is a preclinical small molecule drug discovery initiative by the Warren Center for Neuroscience Drug Discovery (WCNDD) at Vanderbilt University. The program focuses on developing selective agonists for the CB2 receptor, a G protein-coupled receptor primarily located on immune cells such as microglia. Activation of CB2 receptors is associated with anti-inflammatory and neuroprotective effects, making it a promising target for treating neuroinflammation without the psychoactive side effects linked to CB1 receptor activation. The program is currently in the hit-to-lead stage, aiming to identify optimized chemical leads for potential therapeutic application in neurodegenerative and inflammatory disorders.
- Other names
- CB2 agonistCB-2 agonistCB 2 agonistCB2R agonistCB-2R agonistCB 2R agonist
02
Targets
CB (Cannabinoid receptors)
Beyond the preview
Go deeper on cannabinoid receptor 2 agonist.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cannabinoid receptor 2 agonist.